Gemtuzumab ozogamicin and Hepatic impairment/toxicity
Result of checking the interaction of drug Gemtuzumab ozogamicin and disease Hepatic impairment/toxicity for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of gemtuzumab ozogamicin as a single agent, and as part of a combination chemotherapy regimen. Patients who had moderate/severe hepatic impairment prior to treatment were 8.7 times more likely to develop VOD compared to patients without moderate/severe hepatic impairment at baseline. Caution is advised in patients with hepatic impairment, with close monitoring of ALT, AST, total bilirubin, and alkaline phosphatase prior to each dose. After treatment, signs and symptoms of VOD should be monitored frequently; these may include elevations in ALT, AST, total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites. Monitoring only total bilirubin may not identify all patients at risk of VOD. For patients who develop abnormal liver tests, more frequent monitoring of liver tests and clinical signs and symptoms of hepatotoxicity is recommended. Treatment should be discontinued in patients that develop VOD.
Generic Name: gemtuzumab
Brand Name: Mylotarg
Synonyms: Gemtuzumab Ozogamicin